Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, South Korea.
World J Gastroenterol. 2012 Jun 7;18(21):2654-60. doi: 10.3748/wjg.v18.i21.2654.
To evaluate the outcome of sub-centimeter-sized nodules (SCSNs) detected during surveillance for hepatocellular carcinoma (HCC) in patients at risk.
We retrospectively analyzed a total of 142 patients with liver cirrhosis or chronic hepatitis B or C without a prior history of HCC in whom a SCSN was detected during HCC surveillance. We calculated the rate of HCC development from SCSNs in the study population and analyzed the differences in the baseline clinical characteristics and imaging features between the patients with SCSNs that eventually developed into HCC and patients with SCSNs that did not develop into HCC.
During 667 person-years of follow-up, HCC developed in 33 patients. The calculated HCC development rate was 4.9% per year. The cumulative one-, two-, three- and five-year HCC development rates were 5.6%, 10.6%, 14.1% and 20.4%, respectively. Upon baseline comparison, the HCC group was older (54.4 ± 8.3 years vs 48.9 ± 9.4 years; P = 0.003) and had lower albumin levels (3.56 ± 0.58 g/dL vs 3.84 ± 0.55 g/dL; P = 0.012) and higher baseline alpha-fetoprotein (AFP) levels (8.5 ng/mL vs 5.4 ng/mL; P = 0.035) compared to the non-HCC group. Nodule pattern and initial radiologic diagnosis also differed between the two groups. Multivariate analysis revealed that age [P = 0.012, odds ratio (OR) =1.075, 95% confidence interval (CI) =1.016-1.137], sex (P = 0.009, OR = 3.969, 95% CI: 1.403-11.226), and baseline AFP level (P = 0.024, OR = 1.039, 95% CI: 1.005-1.073) were independent risk factors for developing HCC.
The overall risk of HCC development in patients with SCSNs is similar to that in liver cirrhosis patients. Patients with these risk factors need to be closely monitored during follow-up.
评估在肝癌(HCC)监测中发现的亚厘米大小结节(SCSN)在高危患者中的预后。
我们回顾性分析了 142 例无 HCC 既往史的肝硬化或慢性乙型或丙型肝炎患者,这些患者在 HCC 监测中发现了 SCSN。我们计算了研究人群中 SCSN 发展为 HCC 的比率,并分析了 SCSN 最终发展为 HCC 与未发展为 HCC 的患者之间的基线临床特征和影像学特征的差异。
在 667 人年的随访期间,33 例患者发生 HCC。计算的 HCC 发生率为每年 4.9%。累积 1、2、3 和 5 年 HCC 发生率分别为 5.6%、10.6%、14.1%和 20.4%。基线比较时,HCC 组年龄较大(54.4±8.3 岁 vs. 48.9±9.4 岁;P=0.003),白蛋白水平较低(3.56±0.58 g/dL vs. 3.84±0.55 g/dL;P=0.012),基线甲胎蛋白(AFP)水平较高(8.5 ng/mL vs. 5.4 ng/mL;P=0.035)。与非 HCC 组相比,结节模式和初始影像学诊断也不同。多因素分析显示,年龄[P=0.012,比值比(OR)=1.075,95%置信区间(CI)=1.016-1.137]、性别(P=0.009,OR=3.969,95%CI:1.403-11.226)和基线 AFP 水平(P=0.024,OR=1.039,95%CI:1.005-1.073)是发生 HCC 的独立危险因素。
SCSN 患者发生 HCC 的总体风险与肝硬化患者相似。具有这些危险因素的患者需要在随访期间密切监测。